Additional booster doses in patients with chronic lymphocytic
leukemia induce humoral and cellular immune responses to
SARS-CoV-2 similar to natural infection regardless ongoing
treatments: A study by ERIC, the European Research Initiative
on CLL

J 2024

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

CAMPANELLA, A., A. CAPASSO, S. HELTAI, C. TACCETTI, E. ALBI et. al.

Základní údaje

Originální název

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

Autoři

CAMPANELLA, A., A. CAPASSO, S. HELTAI, C. TACCETTI, E. ALBI, Y. HERISHANU, S. HAGGENBURG, T. CHATZIKONSTANTINOU, Michael DOUBEK (203 Česká republika, domácí), M. KATTSTROM, K. GIANNOPOULOS, M. SIMKOVIC, C. MORENO, M. MASSAIA, H. BUMBEA, S. ALSHEMMARI, P. RANGHETTI, E. PEROTTA, F. MARTINI, E. SANT'ANTONIO, M. COLIA, C. COMBI, S. LEVI, A. P. KATER, M. HAZENBERG, I. S. NIJHOF, Q. HOFSINK, C. DEMOSTHENOUS, Jana KOTAŠKOVÁ (203 Česká republika, domácí), J. ZALESKA, F. VRBACKY, A. Mora RAYA, D. BISOGNO, I. E. TRIPOLI, V. M. POPOV, V. ROMAN, N. STAVROYIANNI, M. KARYPIDOU, E. SCARANO, M. LOCATELLI, M. FRENQUELLI, L. SCARFO, K. STAMATOPOULOS a P. GHIA (garant)

Vydání

American Journal of Hematology, MALDEN, USA, WILEY-BLACKWELL, 2024, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.100 v roce 2023

Kód RIV

RIV/00216224:14740/24:00138001

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1002/ajh.27218

UT WoS

001147757200001

EID Scopus

2-s2.0-85183000482

Klíčová slova anglicky

chronic lymphocytic leukemia; SARS-CoV-2

Štítky

NIVB_CEITEC, rivok, RNA4T

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 1. 2025 17:57, Mgr. Eva Dubská

Anotace

V originále

Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.

Citovat

CAMPANELLA, A., A. CAPASSO, S. HELTAI, C. TACCETTI, E. ALBI, Y. HERISHANU, S. HAGGENBURG, T. CHATZIKONSTANTINOU, Michael DOUBEK, M. KATTSTROM, K. GIANNOPOULOS, M. SIMKOVIC, C. MORENO, M. MASSAIA, H. BUMBEA, S. ALSHEMMARI, P. RANGHETTI, E. PEROTTA, F. MARTINI, E. SANT'ANTONIO, M. COLIA, C. COMBI, S. LEVI, A. P. KATER, M. HAZENBERG, I. S. NIJHOF, Q. HOFSINK, C. DEMOSTHENOUS, Jana KOTAŠKOVÁ, J. ZALESKA, F. VRBACKY, A. Mora RAYA, D. BISOGNO, I. E. TRIPOLI, V. M. POPOV, V. ROMAN, N. STAVROYIANNI, M. KARYPIDOU, E. SCARANO, M. LOCATELLI, M. FRENQUELLI, L. SCARFO, K. STAMATOPOULOS a P. GHIA. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. American Journal of Hematology. MALDEN, USA: WILEY-BLACKWELL, 2024, roč. 99, č. 4, s. 745-750. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.27218.

@article{2459757,
   author = {Campanella, A. and Capasso, A. and Heltai, S. and Taccetti, C. and Albi, E. and Herishanu, Y. and Haggenburg, S. and Chatzikonstantinou, T. and Doubek, Michael and Kattstrom, M. and Giannopoulos, K. and Simkovic, M. and Moreno, C. and Massaia, M. and Bumbea, H. and Alshemmari, S. and Ranghetti, P. and Perotta, E. and Martini, F. and Sant'Antonio, E. and Colia, M. and Combi, C. and Levi, S. and Kater, A. P. and Hazenberg, M. and Nijhof, I. S. and Hofsink, Q. and Demosthenous, C. and Kotašková, Jana and Zaleska, J. and Vrbacky, F. and Raya, A. Mora and Bisogno, D. and Tripoli, I. E. and Popov, V. M. and Roman, V. and Stavroyianni, N. and Karypidou, M. and Scarano, E. and Locatelli, M. and Frenquelli, M. and Scarfo, L. and Stamatopoulos, K. and Ghia, P.},
   article_location = {MALDEN, USA},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/ajh.27218},
   keywords = {chronic lymphocytic leukemia; SARS-CoV-2},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ajh.27218},
   volume = {99},
   year = {2024}
}

TY  - JOUR
ID  - 2459757
AU  - Campanella, A. - Capasso, A. - Heltai, S. - Taccetti, C. - Albi, E. - Herishanu, Y. - Haggenburg, S. - Chatzikonstantinou, T. - Doubek, Michael - Kattstrom, M. - Giannopoulos, K. - Simkovic, M. - Moreno, C. - Massaia, M. - Bumbea, H. - Alshemmari, S. - Ranghetti, P. - Perotta, E. - Martini, F. - Sant'Antonio, E. - Colia, M. - Combi, C. - Levi, S. - Kater, A. P. - Hazenberg, M. - Nijhof, I. S. - Hofsink, Q. - Demosthenous, C. - Kotašková, Jana - Zaleska, J. - Vrbacky, F. - Raya, A. Mora - Bisogno, D. - Tripoli, I. E. - Popov, V. M. - Roman, V. - Stavroyianni, N. - Karypidou, M. - Scarano, E. - Locatelli, M. - Frenquelli, M. - Scarfo, L. - Stamatopoulos, K. - Ghia, P.
PY  - 2024
TI  - Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
JF  - American Journal of Hematology
VL  - 99
IS  - 4
SP  - 745-750
EP  - 745-750
PB  - WILEY-BLACKWELL
SN  - 03618609
KW  - chronic lymphocytic leukemia
KW  - SARS-CoV-2
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ajh.27218
N2  - Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
ER  -

CAMPANELLA, A., A. CAPASSO, S. HELTAI, C. TACCETTI, E. ALBI, Y. HERISHANU, S. HAGGENBURG, T. CHATZIKONSTANTINOU, Michael DOUBEK, M. KATTSTROM, K. GIANNOPOULOS, M. SIMKOVIC, C. MORENO, M. MASSAIA, H. BUMBEA, S. ALSHEMMARI, P. RANGHETTI, E. PEROTTA, F. MARTINI, E. SANT'ANTONIO, M. COLIA, C. COMBI, S. LEVI, A. P. KATER, M. HAZENBERG, I. S. NIJHOF, Q. HOFSINK, C. DEMOSTHENOUS, Jana KOTAŠKOVÁ, J. ZALESKA, F. VRBACKY, A. Mora RAYA, D. BISOGNO, I. E. TRIPOLI, V. M. POPOV, V. ROMAN, N. STAVROYIANNI, M. KARYPIDOU, E. SCARANO, M. LOCATELLI, M. FRENQUELLI, L. SCARFO, K. STAMATOPOULOS a P. GHIA. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. \textit{American Journal of Hematology}. MALDEN, USA: WILEY-BLACKWELL, 2024, roč.~99, č.~4, s.~745-750. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.27218.

Přehled o publikaci